Ms. Macfarlane is CEO and a Managing Member of ForSight Labs LLC, an ophthalmic incubator focused on starting companies to bring breakthrough therapies to patients. Over the past 12 years, ForSight has started six VISION companies which have collectively raised over $200M in capital — including Transcend Medical, Inc. (MIGS glaucoma therapy, acquired by ALCON), ForSight Newco II, Inc. (sustained latanoprost, acquired by QLT), NexisVision, Inc. (contact lens technology, licensed), Forsight VISION4, Inc. (sustained protein delivery for posterior segment disease, acquired by ROCHE) and ForSight VISION5, Inc. (sustained bimatoprost, acquired by ALLERGAN). ForSight VISION6, Inc. is an ongoing development stage company operating under a strategic partnership.

Ms. Macfarlane is an inventor on over 25 US patents and brings over 20 years of experience in early stage company creation in both corporate and incubator settings to ForSight. She currently serves as a mentor for the Ferolyn Powell Fellowship Program, and serves on the board of the Fogarty Institute of Innovation in Silicon Valley.